Full Service
Drug Substance
CDMO

- APIs & HPAPIs
- Advanced Intermediates
- Building Blocks
- Enzymes & Proteins
- Peptides
With decades of experience and significant ongoing growth since 2016, there are many reasons to consider Olon as your trusted outsourcing partner. We would love to talk about your needs and demonstrate how we can provide the perfect relationship for you.

**Dynamic Growth from a Stable Base**

Olon is a privately-owned business, started by two families, and is not externally funded in any way or beholden to investors. This brings great financial and operational stability but has also given us the capability to expand organically and dynamically through acquisition with a long-term strategic view of the market and customer relationships – not a short-term, financially-motivated approach.

**World-Class Drug Substance Partner**

- **2,000+** Employees
- **7,320 m³** Reactor Capacity
- **$500 M** Turnover 2019
- **€170 M+** Investment 2019-22

Olon is a global drug substance CDMO (chemistry & fermentation) and one of the largest in Europe, covering the full-service spectrum from early to late phase, supported by a wide range of leading, innovative technologies.

With decades of experience and significant ongoing growth since 2016, there are many reasons to consider Olon as your trusted outsourcing partner. We would love to talk about your needs and demonstrate how we can provide the perfect relationship for you.

### Acquisitions

<table>
<thead>
<tr>
<th>Year</th>
<th>Acquired</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>Acquired Ricerca Biosciences – Chemical Div. USA</td>
</tr>
<tr>
<td>2017</td>
<td>Acquired INFA Group Italy</td>
</tr>
<tr>
<td>2019</td>
<td>Acquired Capua Bioservices Italy, Mahad Site India</td>
</tr>
</tbody>
</table>

**2016**

- Investment 2019-22
- $500 M Turnover 2019

**2017**

- €170 M+ Investment 2019-22

**2019**

- World-Class Drug Substance Partner
Future Growth Strategy
Our acquisitions over recent years have seen Olon expand to 11 manufacturing sites worldwide. We stay mainly in drug substance because we know this is where our experience and knowledge are very high, so we can deliver an optimum solution to our partners. We are pursuing more growth of our CDMO business with further acquisitions over the next few years, ensuring positioning as a leading supplier in the evolving dynamics of the global market.

Secure Global Supply Chain
We invested in a subsidiary in China to provide a local GMP auditing service, ensuring we support our customers with a secure and risk mitigated intermediates supply chain. Our office in Shanghai evaluates suppliers to ensure we have a really good understanding of them. We want to achieve cost optimization, of course, but we also need to know our suppliers meet global standards in business stability, reliability and quality. The Shanghai office also sells intermediates to third parties and registers APIs in China.

Differentiation as a CDMO
Olon has a wealth of experience as a generics manufacturer, as well as being a CDMO. We believe this brings a whole additional level of value to our outsourcing customers, as it differentiates us from pure CDMOs. Our experience and capacity for regulatory support exceed others, having gained approvals for a portfolio of almost 300 APIs and with 370 DMFs worldwide. This expertise directly translates to rapid advancement of your products.

Full-Service Provider
With a strong, multi-faceted R&D team, Olon has the ability and capacity to support you all the way from early phases to commercial supply. We employ a range of advanced technologies and capabilities in hazardous chemistries to meet the needs of companies seeking a full-service drug substance partner to take them all the way. Our US-based Olon Ricerca Bioscience site was acquired to provide all the services required for development of small molecule drug candidates in early-phase clinical trials.

Service Highlights
- Fully equipped R&D laboratory with state-of-the-art analytical instrumentation
- Multiple kilo labs and pilot plants for successful scale-up
- Highly potent APIs (OEL 1-100 µg/m³)
- Chemistry & fermentation-based technologies
- Hazardous chemistries
- Cryogenic technology
- Chromatography
- Biocatalytic transformations
- Gene synthesis, protein expression & production, recombinant proteins
- Microbial fermentation with associated recovery & purification equipment
Expanding Global Network

Olon has 11 manufacturing sites located in Europe, Asia and the United States. This footprint across global markets gives us tremendous flexibility and also highlights our dynamic approach and the growth of our business in recent years. Our plan is to grow our business with further strategic acquisitions.

1. **Olon Segrate**
   Segrate (Milan), Italy

2. **Olon Settimo Torinese**
   Settimo Torinese (Torino), Italy

3. **Capua BioServices**
   Capua (Caserta), Italy

4. **Olon Ricerca Bioscience**
   Concord, OH, USA

5. **Olon Mulazzano**
   Mulazzano (Lodi), Italy

6. **Olon Garbagnate**
   Garbagnate (Milan), Italy

7. **Olon Casaletto Lodigiano**
   Casaletto Lodigiano (Lodi), Italy

8. **Olon Dorno**
   Dorno (Pavia), Italy

9. **Derivados Quimicos**
   Murcia, Spain

10. **Olon API India**
    Mahad, India

11. **P&R Shanghai Supply Chain Sourcing Office**
    Shanghai, China

---

Regulatory Inspections

All of our facilities are regularly inspected by the main international regulatory agencies.

- FDA
- AIFA
- AEMPS Spain
- ANVISA Brazil
- KFDA Korea
- PDMA Japan
- Russian Health Authority
- Italian Veterinary Agency
- COFEPRIS Mexico

---

Olon S.p.A.

Strada Rivolta km 6/7
20053 Rodano (Milano)
Italy

Tel: +39 02 95231
Fax: +39 02 952375056
Email: cdmn@olonspa.it
www.olonspa.com